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Abstract
The evolution of antibiotic resistance carries a fitness cost, expressed in terms of
reduced competitive ability in the absence of antibiotics. This cost plays a key role
in the dynamics of resistance by generating selection against resistance when bac-
teria encounter an antibiotic-free environment. Previous work has shown that
the cost of resistance is highly variable, but the underlying causes remain poorly
understood. Here, we use a meta-analysis of the published resistance literature to
determine how the genetic basis of resistance influences its cost. We find that on
average chromosomal resistance mutations carry a larger cost than acquiring
resistance via a plasmid. This may explain why resistance often evolves by plas-
mid acquisition. Second, we find that the cost of plasmid acquisition increases
with the breadth of its resistance range. This suggests a potentially important
limit on the evolution of extensive multidrug resistance via plasmids. We also
find that epistasis can significantly alter the cost of mutational resistance. Overall,
our study shows that the cost of antimicrobial resistance can be partially
explained by its genetic basis. It also highlights both the danger associated with
plasmidborne resistance and the need to understand why resistance plasmids
carry a relatively low cost.
Introduction
Antimicrobial resistance carries a fitness cost that is
expressed in terms of reduced growth rate, competitive abil-
ity or virulence (reviewed in Andersson 2006; Andersson
and Hughes 2010). This cost of resistance is predicted to
play a key role in the evolutionary dynamics of resistance
because it generates selection against resistance (e.g. Austin
et al. 1997, 1999; Lipsitch et al. 2000; zur Wiesch et al.
2011). This is particularly important when bacteria
encounter an antibiotic-free environment, as occurs when
patients stop using an antibiotic or during transmission
between hosts. Because of this central role, the costs of
resistance have now been measured in well over 100 studies
spanning a wide diversity of resistance mechanisms and
pathogens. These studies have found that the cost of resis-
tance is highly variable. For example, some studies have
reported costs of resistance of >50% (e.g. Binet and Maur-
elli 2005; Norstr€om et al. 2007; Pr€anting and Andersson
2011), while other studies have found that resistance carries
little if any cost (e.g. Pr€anting et al. 2008; Sandegren et al.
2008; Castaneda-Garcia et al. 2009). It is perhaps not sur-
prising that the cost of resistance is highly variable, as it is
influenced by a wide variety of factors. These include the
biochemical effects of specific resistance mutations (e.g.
Andersson et al. 1986; Schrag and Perrot 1996; Macvanin
et al. 2000; Zorzet et al. 2010), as well as the ecological and
genetic background in which the cost of resistance is mea-
sured (e.g. Paulander et al. 2009; Trindade et al. 2009;
Ward et al. 2009; Hall and MacLean 2011). Because of this
complexity, it is unlikely that we will ever be able to fully
explain the cost of resistance.
However, one factor that could potentially play a key role
in the cost of resistance is the underlying genetic mecha-
nism of resistance. At the broadest level, resistance can
evolve either as a result of chromosomal mutation or via
the acquisition of a mobile genetic element (MGE) (Levy
and Marshall 2004; Alekshun and Levy 2007). Intuition
suggests that the cost of resistance is likely to differ between
MGEs and mutations (MacLean et al. 2010). For example,
in addition to resistance genes, MGEs impose an additional
burden on their hosts because they not only carry genes for
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MGE transmission but also encode functions unrelated to
antibiotic resistance (reviewed in Rankin et al. 2011). More
generally, there are potential conflicts of interests between
MGEs and their host bacteria, whereby maximizing MGE
fitness does not maximize host fitness (Mc Ginty and
Rankin 2012). For example, trade-offs can exists between
the vertical and horizontal transmission of MGEs (Mc Ginty
and Rankin 2012), or as a result of kin selection for cooper-
ation among MGEs (Nogueira et al. 2009; Mc Ginty et al.
2011). Conversely, it could be argued that many resistance
mutations are likely to have a greater cost than MGEs, as
they often modify essential genes which are otherwise
highly conserved (Alekshun and Levy 2007).
Importantly, there is also a considerable genetic diversity
of resistance mechanisms within each of these broad clas-
ses. For example, mutational resistance can evolve via
changes to a wide variety of genes (reviewed in Alekshun
and Levy 2007). These include mutations in highly con-
served proteins that play key roles in cellular physiology,
such as ribosomal proteins or RNA polymerase. However,
resistance can also evolve via mutations in accessory genes
that seem to be primarily involved in antibiotic resistance,
such as b-lactamase enzymes, or genes involved in broad
variety of cellular processes, such as efflux pumps. It has
been shown that the biochemical effects of alternative resis-
tance mutations in the same gene can explain why some
resistance mutations are more costly than others (e.g. An-
dersson et al. 1986; Schrag and Perrot 1996; Macvanin
et al. 2000; Zorzet et al. 2010). However, it is still unclear if
certain genetic mechanisms of resistance are consistently
more costly than others. Similarly, intuition suggests that
the genetic diversity that exists within MGEs may influence
the cost of resistance. For example, at one extreme, there
are small plasmids (<10 kb) that may only carry a single
resistance determinant and little else besides the genes
involved in plasmid replication (e.g. San Millan et al.
2009). In contrast, large plasmids (>100 kb) can carry in
excess of 10 resistance determinant as well as a wide variety
of genes involved in other traits (e.g. Sandegren et al.
2012). It is clear that the underlying mechanisms that gen-
erate a cost of MGE acquisition are complex and diverse
(Baltrus 2013). However, it is unclear how this diversity
may impact the cost of resistance.
The majority of papers examining costs of resistance
contain a relatively small number of estimates of the cost of
resistance, although this ranges from one unique mutation
to more than 60, with a mean of 10 isolates per study. Usu-
ally, this is the cost of a single specific mechanism which
provides resistance to only a single family of antibiotics, or
often a small number of MGEs which provide resistance to
one or more antibiotic families. Therefore, to infer the rela-
tive cost of different mechanisms of resistance in is neces-
sary to compare across articles. We therefore performed a
quantitative meta-analysis of published estimates of the fit-
ness cost of resistance. Specifically, we calculated the mean
cost of resistance for many independent papers and then
analysed this data in relation to the various mechanisms of
resistance. Our analysis initially focuses on the methodol-
ogy of measuring fitness costs and whether different types
of assays give comparable outcomes. We then question
whether the genetic basis of resistance determines its cost
by comparing the cost of MGEs and chromosomal muta-
tions. MGEs are highly diverse, but almost all of the esti-
mates of the cost of acquiring MGEs come from plasmids.
We therefore focus our analysis on the cost of evolving
resistance by plasmid acquisition versus the cost of via
chromosomal mutation. We then examine which factors
contribute to the cost of plasmid-mediated resistance, test-
ing whether resistance range (i.e. the degree of multidrug
resistance), plasmid size or host genetic background con-
tributes to the cost of plasmid acquisition. We then exam-
ine chromosomal resistance mutations and test whether the
molecular mechanism or the biochemical basis effect the
cost of resistance. Finally, we analyse papers which studied
multistep resistance evolution and test for the role of epis-
tasis in resistance evolution.
Materials and methods
Literature search
Papers reporting the fitness costs of newly acquired antibi-
otic resistance were initially collected by searching in Pub-
med, Web of Knowledge and Google scholar using the
search terms ‘antibiotic resistance or antimicrobial resis-
tance’ and ‘cost,’ followed by the use of secondary filters
(fitness/biological/physiological). Search results were lim-
ited to papers which were at least available online by the
31st December 2012. No start date was specified. The
search was limited to English language publications. The
search was limited to peer-reviewed articles. Additional
searches were also performed to increase the number of
papers reporting the fitness of mobile genetic elements
(MGE), using the terms ‘fitness’ and ‘plasmid,’ ‘transpo-
son,’ ‘integron’ or ‘genomic island’. We also conducted
manual searches of the bibliographies of each paper which
met our inclusion criteria.
Criteria for inclusion
To be included, papers had to report the results of fitness
assays performed on antimicrobial resistant bacteria and
had to report the findings numerically. This could be of
either the fitness of individual resistant mutants or the
mean fitness of many mutants. Fitness measures had to be
relative to a control strain which only differs in the pres-
ence of the cause of resistance [either a chromosomal
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mutation (SNP, knockout, etc) or acquisition of a MGE].
We therefore excluded papers which compared clinically
isolated mutants which were either susceptible or resis-
tance, as these isolates can differ in more than just the
mechanism of resistance. We chose to analyse the data in
terms of fitness or w, where by definition the susceptible
ancestor was a fitness of 1, with costly mutations having
scores of <1 and beneficial mutations having a score in
excess of 1. If the data were reported in an unstandardized
form (i.e. as raw growth rate or doublings per hour not rel-
ative to a susceptible ancestral strain), manual standardiza-
tion was performed by dividing by the relevant susceptible
ancestor or control, if reported. If a control value was not
reported, this study was excluded. If the data were reported
in terms of selective coefficients (s), this was transformed
into our working measure of w. Papers using competition
indexes, the ratio of resistant to susceptible bacteria at the
end of a set period of time, were excluded because this
measure does not include any aspect of generation/dou-
bling time and consequently is not comparable outside of
the exact context in which it is measured. We also excluded
any mobile elements which had been engineered or altered
by laboratory work, therefore limiting our analysis to wild-
type resistance plasmids. A flowchart of our inclusion pro-
cess is presented in Fig. 1.
Rationale
To avoid biasing our results in favour of whichever paper
measured the highest number of resistant isolates, for the
majority of the analysis, we calculate means for each paper
and therefore each published study is represented by a sin-
gle data point. This is a standard procedure when perform-
ing a meta-analysis as the unit of replication is the
individual study. This is chiefly to avoid confounding dif-
ferent levels of replication (here it would be confounding
variation between resistance mutations with variation
between resistance mechanisms). Additionally, this
approach prevents the analysis from becoming essentially
an analysis of certain mechanisms of resistance which are
highly experimentally tractable. Not only have these mech-
anisms been studied by more papers, but more mutations
per paper when done so. For example, rifampicin-resistant
mutations represent over 25% of individual mutations in
our data set, but only 13% of papers studied rifampicin.
Therefore, performing the analysis at the level of the mech-
anism is more reflective of the diversity of mechanisms of
resistance. However, if a paper had measured resistance to
more than one antibiotic family, these were included as
separate data points. Similarly, if a paper had measured fit-
ness costs for multiple different plasmids, these were also
treated as separate data points. Finally, when testing if dif-
ferent methods provide correlated estimates of fitness for
the same resistant isolate, for obvious reasons, we treat each
resistant isolate as a different data point. If the same plas-
mid had been assayed by multiple papers, an average was
taken from all available measurements. This only applied to
one plasmid (Escherichia coli plasmid R1, two papers).
However, none of the outcomes of statistical tests were
affected if each of these reports were included as separate
data points, or if either of the two reports were solely
included.
Data analysis
Most fitness costs of antimicrobial resistance are presented
as the ratio of the fitness of resistant mutants to the fitness
of its susceptible ancestor. The meta-analysis of so-called
response-ratios is well established (Hedges et al. 1999).
However, to correctly calculate the weightings essential for
a ‘formal’ meta-analysis, it is necessary to know the under-
lying means, standard deviations and sample sizes for the
two values used to calculate the ratio. These are almost
never reported for fitness costs, particularly for competi-
tion experiments that are considered the gold-standard for
measuring the fitness of microorganisms. Although other
methods for weighting studies do exist, given the small
sample size of most studies reporting fitness costs (mean of
10 isolates, median of four, mode of one isolate), these
methods would not result in accurate weightings (generally
n = 5 is required for most weighting procedures) (Hedges
et al. 1999). We therefore perform an unweighted analysis
of published fitness costs using conventional statistics such
as ANOVA, t-tests, Pearson’s correlations, etc. Reviews of
meta-analysis suggest this approach when published data
are missing information required for formal meta-analysis
(Gurevitch and Hedges 1999; Gurevitch et al. 2001). How-
ever, these reviews also caution that if some papers have farFigure 1 Overview of the inclusion process.
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greater sample sizes or sample variances than others, the
results of unweighted analyses can be inaccurate or possibly
meaningless. However, we would argue that this concern is
less applicable when analysing laboratory measurements of
microbial fitness. Although undoubtedly there is some
study variance in the degree accuracy of these measure-
ments, it is highly unlikely to be to the same extent as
encountered with medical or ecological meta-analyses.
Results
Measuring the cost of resistance
After employing our criteria for inclusion, our search
yielded 77 papers reporting the fitness cost of newly
acquired antimicrobial resistance (Appendix S1), which
represents a total of 822 independent resistant mutants.
These papers used one or more of three broad methodolo-
gies to assess the fitness costs of resistance. Firstly, there are
direct competition experiments against an ancestral strain
performed in vitro (455 isolates). Secondly, there are in vitro
proxy measures of fitness such as growth rates, doubling
times, maximum yields, etc. (367 isolates). These measures
are then standardized against the ancestral strain and used
to infer the outcome of direct competitive interactions.
Thirdly, there are competition experiments performed in
vivo, or strictly speaking inside a mouse (23 isolates). Con-
veniently, several manuscripts have multiple methods on
the same isolate, which thereby allows a comparison of the
various methods. Specifically, 23 isolates (five papers) by
both an in vitro and in vivo method, and 55 isolates (12
papers) had been assayed by both in vitro methods. If we
use each paper as an independent data point, there is no
significant difference in the mean cost of resistance between
the in vitro and in murine fitness assays (Fig. 2A; paired
t-test on mean cost per manuscript, in vitro versus in mur-
ine, t = 1.17, df = 4, P = 0.307), nor between the two types
of in-vitro assays (Fig. 3A; paired t-test on mean cost per
manuscript, growth rate versus competition, t = 0.394,
df = 11, P = 0.703). This suggests that if a particular resis-
tance mechanism is found to be either high or low cost by
one assay, it is likely to be found to have the same relative
cost by another methodology. Similarly, there are also sig-
nificant correlations in fitness for individual resistance iso-
lates which have been assayed in more than one way
(Fig. 2B: in vitro vs In murine, df = 21, r = 0.814,
P < 0.001; Fig. 3B: competition vs growth rate, df = 53,
r = 0.763, P < 0.001). Both of these correlations remain
significant if we control for the differences in the means of
different papers (partial correlation between in vitro vs in
murine controlling for differences between manuscripts,
df = 20, r = 0.775, P < 0.001; partial correlation between
competition versus growth rate controlling for differences
between manuscripts, df = 52, r = 0.752, P < 0.001).
Due to the small sample size of in vivo measurements of
the cost of resistance, we henceforth analyse only the
in vitro measurements of the cost of resistance. We treat
both proxy and direct competitive assays as equivalent
measures of fitness. Therefore, for isolates assayed with
both in-vitro assays, we calculate the average for each iso-
late prior to calculating the average for that study. This is
necessary due to many manuscripts only performed both
types of assays on a subset of isolates.
Plasmid-mediated resistance carries a small cost
In general, antimicrobial resistance can either evolve by
chromosomal mutation or by the acquisition of a mobile
genetic element which carries one or more resistance gene.
Most estimates of the cost of resistance come from studies
that have measured the cost associated with chromosomal
resistance mutations (60 studies, 78 antibiotic by study
combinations, 760 total mutants). Although a broad diver-
sity of MGEs can carry resistance genes, plasmids are by far
the best characterized vectors of horizontal resistance trans-
mission. Indeed, we found a large number of estimates of
the cost of carrying plasmids containing resistance genes
(A)
(B)
Figure 2 (A): There is no significant difference between the cost of
antimicrobial resistance measured in-vitro (grey bars, mean fitness 
SEM) or in a mouse (white bars, mean fitness  SEM). Each pair of bars
represents a separate published paper. 2(B): Fitness in a mouse corre-
lates with fitness in-vitro. Each set of symbols represents a different
paper, with each point an independent mutation.
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(49 plasmids from 16 studies), whereas we could only find
costs for seven examples (from 4 papers) of other types of
mobile elements which matched our criteria. We therefore
decided to focus the analysis of the cost of MGEs exclu-
sively on plasmids.
To determine whether the genetic basis of resistance
influences its cost, we compared the cost of resistance
mutations and plasmids carrying resistance genes (Fig. 4).
The average cost of acquiring resistance via a plasmid
(0.91  0.024) is lower than the cost of resistance due to
chromosomal mutations (0.79  0.024). This difference is
statistically significant when treating each plasmid as an
independent observation (Fig. 4; one-way ANOVA,
F1,125 = 12.421, P < 0.005) or, more conservatively, by
treating each study as an independent observation (one-
way ANOVA, F1,92 = 5.14, P < 0.05). However, it could be
argued that this is an inaccurate comparison, as the major-
ity of plasmids carry resistance to multiple different antimi-
crobials. In contrast, the majority of mutational resistance
mechanisms only result in high-level resistance to one fam-
ily of antimicrobials. There are notable exceptions to this
such as mutations effecting permeability (i.e. efflux pumps
and porins), as well as mutations effecting global metabo-
lism such as mutations leading to small colony variants.
However, mutations which could directly result in multi-
drug resistance only represent 13.1% of our sample (10/78
chromosomal mechanisms). In contrast, MDR-plasmids
represent 90% of the plasmids (43/49) in our sample, and
on average, these plasmids confer resistance to 3.7 different
antimicrobials. Therefore, if we perform a more appropri-
ate comparison and only analyse mono-resistant mutations
and plasmids, we still find a significant difference between
the two genetic sources of resistance (F1,72 = 7.15,
P < 0.01). The mean fitness for mutational resistance
remains essentially unchanged (0.805  0.022), whereas
mono-resistant plasmids has now increased to 1.02 (
0.112).
The fitness costs of plasmid acquisition
As the cost of mono-resistant plasmids is lower than the
cost of all plasmids, it could be predicted that the cost of a
plasmid should increase with increasing levels of multidrug
resistance. Indeed, there is a significant correlation between
the cost of a plasmid and the number of antimicrobial fam-
ilies to which that plasmid confers phenotypic resistance
(Fig. 5A; df = 47, r = 0.285 P < 0.05). This is not an
artefact of larger plasmids carrying more resistances and
thereby a greater number of other costly traits not associ-
ated with resistance, although larger plasmids do on aver-
age possess a greater range of resistances (df = 46,
r = 0.428, P < 0.005). Specifically, plasmid size does not
correlate with its fitness cost (Fig. 5B; df = 46, r = 0.127,
P = 0.390), nor does adding plasmid size improve the
strength of the correlation between resistance range and fit-
ness (inclusion of plasmid size as a term in linear regression
of fitness cost against resistance range: t = 0.003,
P = 0.997). It is important to note that the number of phe-
notypic resistances a plasmid carries is not synonymous
(A)
(B)
Figure 3 (A): There is no significant difference between the cost of
resistance measured by a proxy (such as growth rate, density at a set
time, etc.) (grey bars, mean  SEM) or by direct competition assays
(white bars, mean  SEM). Each pair of bars is a separate published
paper. 3(B): Competitive fitness correlates with growth rate. Each set of
symbols represents a different paper, with each point an independent
mutation.
Figure 4 Evolving resistance by acquiring a plasmid has a smaller fit-
ness cost than evolving resistance by mutation (bars show mean fitness
 SEM). The bars are the means of 78 mechanisms of mutational resis-
tance, 49 plasmids, and 7 other mobile genetic elements, respectively.
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with the number of resistance genes a plasmid encodes.
Many resistances require multiple genes to work, while
many plasmids carry multiple independent resistance genes
for one antimicrobial. As data on the number of resistance
genes carried by a plasmid is scarcer, we were unable to
include this information in the analysis.
Chromosomal genes contribute to the cost of plasmids
In several papers (n = 5), the cost of a plasmid was assayed
in multiple different bacterial hosts, while in several other
papers (n = 6), the costs of several different plasmids have
been assayed on a single host. It is striking that the variance
for the same plasmid on different na€ıve hosts often appears
to be as large as the variation between different plasmids
on one host. If the same plasmid has different costs in dif-
ferent hosts, it implies that the cost of a plasmid is caused
as much by properties of the bacteria as by any property
the plasmid itself. Ideally, factorial designs would be used,
where the costs of different plasmids are assayed across the
same set of host strains, to simultaneously assess the
importance of host and plasmid properties in determining
the cost of plasmid acquisition. This would put the propor-
tion of variance due to host properties in the context of a
relevant biological comparison. However, from the existing
published data, the mean coefficient of variation in fitness
when a plasmid is assayed across multiple hosts is 9.8%.
Interesting, this is not significantly different (Fig. 6; one-
way ANOVA: F1,9 = 0.917, P = 0.363) from the mean coeffi-
cient of variation in fitness when multiple plasmids are
assayed on one host (16%). This suggests that host genes or
traits are at least as important as any plasmid gene or trait
in determining the fitness cost of a plasmid.
Biochemical mechanisms of chromosomal resistance
mutations
Chromosomal mutations which result in resistance can do
so by a variety of mechanisms, which can broadly be
divided into target-site and non-target-site mechanisms
(Andersson and Hughes 2010). The former of these arises
due to mutations in the gene encoding the protein to which
the antibiotic physically binds. The latter group is far more
diverse. Common mechanisms include up-regulation of
so-called defence genes, such as efflux pumps and enzymes
that degrade or modify antibiotics, for which we identified
six papers (Lindgren et al. 2005; Marcusson et al. 2009;
Abdelraouf et al. 2011; Guo et al. 2012; Kunz et al. 2012;
Olivares et al. 2012) and two papers (Marciano et al. 2007;
Moya et al. 2008), respectively. We also identified several
papers where resistance was due to reduced expression or
loss of function mutations. These include reduced expres-
sion of porin genes (Abdelraouf et al. 2011), loss of reduc-
ing enzymes (Sandegren et al. 2008), and loss of
(A)
(B)
Figure 5 (A): The fitness cost of acquiring a plasmid increases in pro-
portion to the resistance range of a plasmid. The resistance range of a
plasmid is defined as the number of antimicrobial families to which phe-
notypic resistance is gained upon acquiring the plasmid, as reported in
the relevant paper. Symbols represent mean fitness ( SEM), with a
sample size of 6, 6, 14, 7, 8, 5, 1, and 2 plasmids, from left to right,
respectively. 5(B): The size of a plasmid (DNA KB) does not significantly
correlate with its fitness cost. Each point represents the published fit-
ness cost of acquiring a resistance plasmid.
Figure 6 Both plasmid factors and bacterial factors contribute the size
of the cost of acquiring a plasmid. Bars show the mean coefficient of
variation ( SEM) for papers which either measured the cost of several
different plasmids on a single host, or measured the cost of a single
plasmid in different bacterial hosts.
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intracellular transporters (Pr€anting et al. 2008; Castaneda-
Garcia et al. 2009). We also identified so-called by-pass
resistance to the peptide deformylase actinonin (Paulander
et al. 2007; Zorzet et al. 2012), where resistance evolves via
bypassing the need for the inhibited enzyme, as well as
resistance to lysostaphin via alterations to cell-wall struc-
ture (Kusuma et al. 2007). Finally, we identified several
papers reporting the cost of resistance due to small colony
variants (SCVs) (Norstr€om et al. 2007; Seaman et al. 2007;
Pr€anting and Andersson 2011). This is where a mutation
markedly reduces the rate of a cell’s respiration, and conse-
quently results in resistance to a wide diversity of antimi-
crobials, heavy metals, and other stresses.
Overall, we find that the molecular basis of chromosomal
resistance mutations significantly affects the cost of resis-
tance (Fig. 7A; one-way ANOVA on all mechanisms with at
least two data points: F5,67 = 7.41, P < 0.001). However,
given the diversity of mechanisms and the number of repli-
cates of each mechanism, it is unsurprising that post hoc
analysis does not add much additional detail. Specifically,
SCVs are found to be more costly than all of the other
mechanisms of resistance (Bonfferoni corrected t-tests,
P < 0.05 in all cases), while reduced intracellular transport
is also significantly less costly than by-pass resistance to ac-
tinonin. This lack of significant variation may reflect the
actual biology but may also be due the scale of our analysis
and consequently the many other factors which will co-vary
with resistance mechanism.
Target-site resistance can be additionally divided based
on the biological process targeted by antibiotics. Broadly
this encompasses inhibitors of DNA-topoisomerases (flu-
oroquinolones, n = 11 papers), RNA-polymerase inhibi-
tors (rifampicin and myxopyronin n = 17 papers),
translation inhibitors (aminoglycosides, macrolides, linezo-
lid, mupirocin, and fusidic acid (n = 29) and cell-wall syn-
thesis inhibitors (beta-lactams, n = 1, not included in
statistics). The cost of resistance varied significantly
between the different biochemical pathways being inhibited
(Fig. 7B; one-way ANOVA: F2,54 = 4.49, P < 0.05). Specifi-
cally, mutations in DNA-topoisomerases were less costly
than mutations effecting translation (post hoc Tukey test,
mean difference = 0.180, P < 0.05). Mutations in RNA-
polymerase genes were not significantly different from
either mutations affecting translation (post hoc Tukey test,
mean difference = 0.054, P = 0.908), or mutations affect-
ing DNA-topoisomerases (post hoc Tukey test, mean dif-
ference = 0.126, P = 0.181). It is important to note that
these results are for single mutations, and therefore, it can-
not be inferred that clinically evolved resistance will neces-
sarily reflect this pattern. Clinical isolates often possess
multiple resistance mutations, but the exact number varies
between different antimicrobials. For example, fluoroqui-
nolone-resistant isolates normally possess multiple muta-
tions (e.g. Jalal et al. 2000; Wang et al. 2001; Weigel et al.
2001), while in contrast rifampicin resistance is normally
due to a single mutation in an RNA-polymerase gene (e.g.
Wehrli 1983; Somoskovi et al. 2001).
The role of epistasis
The evolution of high levels of resistance to an antibiotic
via mutation sometimes involves the substitution of multi-
ple mutations. For example, the majority fluoroquinone-
resistant clinical isolates harbour multiple mutations in
DNA-topoisomerases and often carry mutations in efflux
pump repressors (e.g. Jalal et al. 2000; Wang et al. 2001;
Weigel et al. 2001). If interactions between resistance
mutations are additive, then the fitness of a strain carrying
multiple resistance mutations is equal to the product of the
fitness of strains carrying each mutation individually
(reviewed in de Visser et al. 2011). For example, the fitness
of a strain carrying mutations A and B, wAB, will be equal
to wAb* wbA. In this scenario, the cost of resistance will
(A)
(B)
Figure 7 (A): The mechanistic basis of chromosomal resistance signifi-
cantly affects the cost of resistance. Bars represent mean fitness (
SEM, if at least 2 published reports exist). 7(B): the metabolic pathway
affected by target-site resistance significantly affects the cost of resis-
tance. Bars represent the mean fitness cost of a single resistance muta-
tion to either a DNA-topoisomerase inhibitor, a transcription inhibitor,
or a translation inhibitor.
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increase linearly with the number of resistance mutations
acquired. Alternatively, it is possible that epistasic interac-
tions between resistance mutations shape the cost of resis-
tance. If positive epistasis occurs between resistance
mutations, the fitness of strains carrying multiple muta-
tions will be greater than expected from an additive model,
that is, wAB> wAb* wbA. Positive epistasis will promote the
evolution of resistance, because successive resistance muta-
tions will incur diminishing costs; if epistasis is strongly
positive, it is even conceivable that strains carrying multiple
mutations that are individually costly may even pay no cost
for resistance. Under negative epistasis, the fitness of strains
carrying multiple resistance mutations is less than what
would be expected under an additive model, that is, wAB<
wAb* wbA. Negative epistasis will prevent the evolution of
resistance, because successive resistance mutations will
aggravate each other’s’ costs.
We identified 13 papers which had analysed the stepwise
evolution of resistance. Although some of these papers had
compared stepwise resistant isolates with up 5 mutations,
due to progressively smaller sample sizes, our analysis will
focus on strains with just one and two mutations. Overall,
strains harbouring two resistance mutations are signifi-
cantly less fit than strains with one resistance mutation
(Fig. 8A; paired t-test: t = 2.47, df = 12, P < 0.05). This is
a key result, because it implies that there is an overall cost
to increasing antibiotic resistance. To test for epistasis, for
each paper, we calculated the expected fitness of strains
with 2 mutations if both mutations simply had the same
effect as the mean first mutation (i.e. taking the square of
the fitness cost of first-order resistant strains). Subtracting
this expected fitness from the observed fitness of second-
order mutants reveals no significant epistasis (one-sample
t-test: t = 1.21, df = 12, P = 0.250). However, if we ignore
the direction of epistasis by using the absolute of the differ-
ence between predicted and observed fitness, we find that
the fitness costs of the second mutation to fix is signifi-
cantly nonrandom (one-sample t-test: t = 3.32, df = 12,
P < 0.01). In other words, the first test failed to detect epis-
tasis because some papers found significant negative epista-
sis, while others found significant positive epistasis.
These 13 papers have used a variety of different methods
to generate the stepwise increases in resistance. Ten of these
papers used constructs of independently evolved laboratory
mutations, while the remaining three papers used combina-
tions of alleles which had evolved in clinical environments
which were then transferred onto isogenic backgrounds for
further analysis. The key difference between these methods
is that the lab studies examine interactions between artifi-
cially generated combinations of mutations, whereas clini-
cal studies examine interactions between mutations that
were naturally assembled into combinations. Interestingly,
we find no significant epistasis for these three papers which
utilized clinical alleles (one-sample t-test: t = 1.69, df = 2,
P = 0.232), although the sample size here is very small. In
contrast, for the 10 papers using laboratory alleles the
analysis reveals significant negative epistasis (one-sample
t-test: t = 2.36, df = 9, P < 0.05), and therefore laboratory
evolved second-order resistance mutations have signifi-
cantly higher costs than predicted from the effects of the
first-order mutations. There is also a significant difference
in epistasis between the two different sources of alleles
(Fig. 8B; one-way ANOVA, clinical versus laboratory,
F1,11 = 5.93, P < 0.05).
Discussion
One of the most important challenges in understanding of
antimicrobial resistance is to determine whether there are
any broad, general features which can be applied across
(A)
(B)
Figure 8 (A): The cost of stepwise resistance increases with each suc-
cessive step. Bars show mean relative fitness (SEM) from 13 papers
which measured the stepwise evolution of resistance. 7 of these papers
only compared strains with 1 or 2 resistance alleles or mutations. The
remaining 6 then went on to study a third level of resistance, and 3 of
these also reported the costs of acquiring a fourth and fifth resistance
mutation. 8(B): There is significant negative epistasis between labora-
tory evolved alleles, but no significant epistasis between clinically
evolved alleles. Bars represent the mean difference between no epistasis
(where the cost of a second mutation is the same as the first), and what
is actually observed from the 13 papers. A negative value indicates a
greater than expected cost, and a positive result a smaller than
expected cost.
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biological systems (Martinez et al. 2007; zur Wiesch et al.
2011). A considerable amount of work has been performed
to determine the genetic and biochemical basis of antimi-
crobial resistance. Here, we attempted to determine
whether the molecular basis of antimicrobial resistance can
be connected to fitness at a broad scale. We find that the
genetic basis of resistance plays a key role in determining
its costs; specifically, we find that evolving resistance by
plasmid acquisition tends to carry a much smaller cost than
evolving resistance de novo by chromosomal mutation. In
principle, the low cost of plasmid-associated resistance
could help to explain why plasmids play such a predomi-
nant role in the evolution of resistance, particularly when
combined with their ability to spread horizontally. In con-
trast, we found little evidence of systematic variation in fit-
ness between alternative biochemical mechanisms of
resistance. We are not arguing that the biochemical basis of
resistance does not influence its costs; on the contrary, the
biochemical effects of resistance can explain why some
resistance mutations to the same antimicrobial are more
costly than others (e.g. Andersson et al. 1986; Schrag and
Perrot 1996; Macvanin et al. 2000; Zorzet et al. 2010). Per-
haps, the diversity of resistance mutations to each antibi-
otic is responsible for the lack of explanatory power,
although this could also be an artefact of the scale of our
analysis.
Why does plasmid-mediated resistance carry a small cost?
One of the most striking features of the evolution of anti-
microbial resistance by chromosomal mutations is the high
degree of conservation in the molecular basis of resistance.
Resistance often evolves due to mutations in the same con-
served sequences in different species (Alekshun and Levy
2007), and sometimes even due to the same substitutions.
The implication of this is that the evolution of resistance by
chromosomal mutation in a bacterial lineage represents a
true de novo instance of resistance evolution. It is therefore
unlikely that bacteria will initially possess adaptations to
offset the cost of mutations in these genes, although it has
been shown that bacteria can rapidly acquire such adapta-
tions through compensatory evolution (reviewed in An-
dersson and Hughes 2010). In contrast, when bacteria
evolve resistance by acquiring a plasmid they are obtaining
a resistance determinant that has already experienced selec-
tion to minimize its cost in previous hosts. For example, it
has been shown that plasmids genes are enriched for bio-
synthetically cheap amino acids relative to analogous chro-
mosomal genes (Nogueira et al. 2009), demonstrating
selection to minimize the cost of plasmid-encoded pro-
teins. Additionally, bacteria can be ‘cured’ of plasmids by
segregational loss during cell division. It is therefore possi-
ble that when bacteria evolve resistance by acquiring a plas-
mid, they are simply re-acquiring a plasmid that they
previously carried during their evolutionary past. If this is
the case, then bacterial chromosomes may already carry
compensatory mutations that offset the cost of a newly
acquired plasmid. In support of this argument, laboratory
studies have shown that bacteria can rapidly adapt to plas-
mids carrying resistance genes, eliminating the cost of plas-
mid carriage. Crucially, this adaptation is as likely to be
due to mutations on the host’s chromosome as it is a muta-
tion on the plasmid itself (Bouma and Lenski 1988; Dahl-
berg and Chao 2003; Dionisio et al. 2005). In some
systems, this can result in hosts which harbour plasmids
being fitter than their plasmid-free ancestors (Dionisio
et al. 2005; Starikova et al. 2013). This host-plasmid coevo-
lution could also explain why the cost of the same plasmid
is so variable between different bacterial hosts – hosts in
which a plasmid has a low fitness cost may have had a
longer or more recent history of carrying that type of plas-
mid.
However, plasmid acquisition was still found to be
costly, and this cost increased with increasing plasmid
resistance range. In contrast, the size of a plasmid did not
correlate with its fitness cost. As the number of total genes
carried by a plasmid is correlated with its size, this is sug-
gestive that resistance genes are more costly than the
majority of plasmid-encoded traits. This could be due to
resistance genes being relatively recent additions to the
traits carried by plasmids; plasmids isolated prior to the
antimicrobial-era do not carry antimicrobial resistance
(Hughes and Datta 1983). Therefore, it is likely that the
genes which encode resistance have had less time to adapt
to being carried by plasmids than the majority of plasmid
carried-traits.
Epistasis and the evolution of resistance by mutation
Although plasmid acquisition provides bacteria with a
potentially easy route to evolving resistance, spontaneous
mutation is an important mechanism of resistance evolu-
tion. For example, mutation is the dominant mechanism of
resistance evolution in the intracellular parasite M. tuber-
culosis (Sandgren et al. 2009; Muller et al. 2013) and in the
opportunistic pathogen P. aeruginosa (Livermore 2002;
Bonomo and Szabo 2006; Lister et al. 2009). The classic
paradigm is that resistance evolution occurs by a few muta-
tions of large effect. However, there is growing evidence
that high levels of antibiotic resistance evolve by the substi-
tution of multiple mutations that confer resistance to the
same antibiotic (Weinreich et al. 2006; Bruchmann et al.
2013; Farhat et al. 2013; Zhang et al. 2013). When resis-
tance evolves by mutations in multiple genes, epistatic
interactions between resistance mutations have the
potential to influence the overall cost associated with resis-
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tance. Previous work has shown that epistasis between
mutations that confer resistance to alternative antibiotics is
widespread, and there is an overall tendency towards posi-
tive epistasis (Trindade et al. 2009; Ward et al. 2009). We
find that epistasis is also widespread between pairs of muta-
tions that confer resistance to the same antibiotic, which is
in agreement with previous work on the genetics of rifam-
picin resistance (Hall and MacLean 2011). Our analysis
makes the intriguing suggestion that selection in clinical
environments leads to the evolution of combinations of
resistance mutations that pay a minimal epistatic cost of
resistance. This analysis also suggests that there is consider-
able scope for exploring the role of epistasis in resistance
evolution in clinical environments.
Biases in the cost of resistance literature
The cost of resistance has now been measured in well over
100 studies, and this literature provides an important
resource for understanding the evolution of antibiotic
resistance. However, it is important to point out that there
are some important biases in the cost of resistance litera-
ture. Perhaps most importantly, this reviewed focussed on
in-vitro measures of fitness cost, for which a considerable
amount is known. There is considerably less work on the
evolutionary dynamics of resistance in-vivo, such as in
patients who have been treated with antibiotics or in envi-
ronments that are involved in pathogen transmission (but
see Gustafsson et al. 2003). There is also a bias in the litera-
ture towards working with antibiotics that are experimen-
tally tractable, rather than clinically relevant. For example,
b-lactams are currently the most commonly used antimi-
crobials (Goossens et al. 2007; Adriaenssens et al. 2011).
However, there is considerably more known about the fit-
ness costs of rifampicin and aminoglycoside resistance,
both of which are less commonly used. This is not say
research about rifampicin and aminoglycoside resistance is
not important and interesting. However, it is noticeable
that the costs associated with these mechanisms of resis-
tance are far better characterized than the costs of b-lactam
resistance. Lastly, estimates of the cost of resistance associ-
ated with mobile genetic elements are lacking. Resistance
genes are horizontally transferred by a wide diversity of
mobile genetic elements, including plasmids, transposons,
bacteriophages, genomic islands, integrons, and ICEs
(reviewed in Barlow 2009). However, only costs associated
with resistance carrying plasmids have been studied in any
detail. Notable exceptions to this include the four transpo-
sons included in our analysis (Enne et al. 2005; Foucault
et al. 2010; Starikova et al. 2012), as well as several papers
published since our search was performed (e.g. Knight
et al. 2013; Starikova et al. 2013). There are also costs of
MGE acquisitions where the genetic background was not
controlled (e.g. Foucault et al. 2009; Corich et al. 2010).
However, in general, this is an area where considerable
extra research is required.
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